VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
VolitionRx (NYSE AMERICAN: VNRX) will host a conference call on Wednesday, April 1, 2026 at 8:30 a.m. U.S. Eastern Time to discuss full fiscal year 2025 financial results and provide a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) will host a conference call on Wednesday, April 1, 2026 at 8:30 a.m. U.S. Eastern Time to discuss full fiscal year 2025 financial results and provide a business update.
The live audio webcast will be available online, with telephone dial-ins for U.S./Canada, U.K., and international participants and a replay accessible until April 15, 2026 (Conference ID 13759627).
Senior management and scientific officers will present and take questions about 2025 events, subsequent developments, and upcoming milestones.
Details
News Market Reaction – VNRX
On Mar 26, the first trading day after this news, VNRX closed 0.89% above the previous close.
Data tracked by StockTitan Argus for the Mar 26 session.
Key Figures
- Conference date
- April 1, 2026
- Full fiscal year 2025 earnings and business update call
- Conference time
- 8:30 a.m. U.S. Eastern Time
- Scheduled start time of earnings call
- Replay end date
- April 15, 2026
- Telephone replay availability for the call
- Conference ID
- 13759627
- Dial-in conference identifier for the earnings call
- U.S. dial-in
- 1-877-407-9716
- Toll-free U.S. & Canada participant number
- U.K. dial-in
- 0 800 756 3429
- Toll-free U.K. participant number
- Registered shares
- 17,968,090 shares
- Common stock registered for resale under effective S-3
- Ownership caps
- 4.99% and 19.99%
- Caps on Lind Global’s holdings from notes and warrants
Previous Conferences,earnings Reports
-
Announced Q3 2025 earnings and business update conference call logistics.
-
Scheduled Q2 2025 earnings call with access details and replay info.
-
Set date and dial-in details for Q1 2025 earnings and business update.
-
Announced timing and access for full-year 2024 earnings conference call.
-
Planned Q3 2024 earnings call and business update with replay details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call to take place on Wednesday, April 1 at 8:30 a.m.
Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference Call
Date: Wednesday, April 1, 2026
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13759627
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr. Andrew Retter, Medical Consultant and Dr. Jake Micallef, Chief Scientific Officer. The call will provide an update on important events that have taken place in 2025, subsequent events and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until April 15, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-fiscal-year-2025-earnings-conference-call-and-business-update-302725247.html
SOURCE VolitionRx Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.